Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Visit old site
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 2604


 
 Table of Contents  
ORIGINAL ARTICLE
Year : 2014  |  Volume : 6  |  Issue : 11  |  Page : 558-565

Genetic variants of interleukin-10 gene promoter are associated with schizophrenia in Saudi patients: A case-control study


1 Department of Neuropsychiatry, Research Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
2 Department of Psychiatry, Research Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
3 Department of Molecular Biology and Genetics, Research Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia

Date of Web Publication26-Nov-2014

Correspondence Address:
Abdulrahman Al-Asmari
Senior Consultant and Director of Research Center, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh 11159
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1947-2714.145466

Rights and Permissions
  Abstract 

Background: Interleukin-10 (IL-10) gene is considered as a potential candidate gene in schizophrenia association studies. The polymorphisms on IL-10 gene have been reported to be linked with susceptibility to the development of schizophrenia within consistent results. Aims: The aim of this case-control study was to examine whether the -1082A/G, -819T/C, and -592A/C polymorphisms in IL-10 gene are implicated in schizophrenia development in the Saudi population. Materials and Methods: Molecular genotyping of IL-10 gene polymorphisms was performed to analyze the genotypes and alleles distribution of three single-nucleotide polymorphisms (SNPs) in patients (n = 181) and healthy individuals as control group (n = 211). Results: The frequencies of GA genotype at -1082, and CC genotype at positions -592 and -819 were significantly higher in schizophrenia patients compared to healthy subjects suggesting that GA, CC, and CC genotypes are susceptible to schizophrenia. The ACC haplotype known to be associated with intermediate production of IL-10 are more prevalent in our schizophrenia patients. On the other hand, genotypes -1082 GG, -819 CT, and -592 CA of IL-10 were more prevalent in healthy controls suggesting protective effects of GA, CT, and CA genotypes against schizophrenia. There was no significant association of IL-10 polymorphisms with sex or positive or negative symptoms of schizophrenia. Conclusion: This study indicates that the IL-10 gene polymorphisms play a significant role in the etiology of schizophrenia in Saudi Arabians patients.

Keywords: Interleukin-10, Polymorphism, Saudis, Schizophrenia


How to cite this article:
Al-Asmary SM, Kadasah S, Arfin M, Tariq M, Al-Asmari A. Genetic variants of interleukin-10 gene promoter are associated with schizophrenia in Saudi patients: A case-control study. North Am J Med Sci 2014;6:558-65

How to cite this URL:
Al-Asmary SM, Kadasah S, Arfin M, Tariq M, Al-Asmari A. Genetic variants of interleukin-10 gene promoter are associated with schizophrenia in Saudi patients: A case-control study. North Am J Med Sci [serial online] 2014 [cited 2019 Nov 18];6:558-65. Available from: http://www.najms.org/text.asp?2014/6/11/558/145466


  Introduction Top


Schizophrenia (MIM 181500) is one of the most disabling psychiatric disorders affecting around 24 million people worldwide, with a prevalence ranging from 0.7 to 1.1% and with a lifetime morbidity risk of 0.5-2.7%. [1],[2] Schizophrenia affects men and women equally; however, most researchers agree that the onset of schizophrenia in women appears later than in men. [3] Due to its early age of onset and the lifelong disability, schizophrenia is considered as one of the most catastrophic mental illnesses. [4],[5] One of the most vital aspect for developing treatment and prevention strategies for schizophrenia is identifying the causes of the disorder. Research over the decades has led us to suggest that the etiology of schizophrenia involves the interplay of complex polygenic influences and environmental risk factors operating on brain maturational processes.

Schizophrenia has long been considered as a disorder involving immune system. Possible role of the immune response system in the pathogenesis of schizophrenia is indicated by several authors and meta-analyzed. [6],[7],[8],[9],[10] An immune response shifting from Type 1 to Type 2 is one of the strong proposition supporting immunoinflammatory origin of schizophrenia. [11],[12] Variations in the concentration of cytokines in patients with schizophrenia have also been reported. [7] It has been shown that the concentration of cytokines in blood serum in patients suffering from schizophrenia varies depending on whether the patient is in active or resting phase of the disease. [13]

Interleukin (IL)-10, a Th2 cytokine is one of the many cytokines that seems to play a vital role in immune response that is generated in brain. Increased level of cytokine IL-10 in the cerebrospinal fluid of schizophrenics has been reported. [14],[15] Production of cytokine IL-10 is controlled by IL-10 gene located on human chromosome 1 (1q31-q32) in a region reported to be related to schizophrenia in genetic association studies. [16] Given the strong hereditary background of schizophrenia, it is assumed that genetic factors may also underlie immune system deregulation and aberrant cytokine production observed in schizophrenia. IL-10 is secreted by a variety of cells including monocytes/macrophages, T-cells, β-cells, and mast cells. It is responsible for various functions. It shifts the Th1/Th2 balance by downregulating the Th1 responses and by suppression of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) secretion.[17] A number of single-nucleotide polymorphisms (SNPs) were reported in the proximal and distal regions of the IL-10 gene. [18],[19] Three promoter polymorphisms (rs18000896-1082A/G, rs1800871-819T/C, and rs1800872-592A/C) are reportedly involved in IL-10 transcription rate, thereby directly affecting its production level. [19],[20] The -1082G, -819C, and -592C (GCC) alleles have been associated with elevated levels of IL-10 production, [21] while ACC and ATA haplotypes exhibit intermediate and low IL-10 gene transcription, respectively. [22] These polymorphisms on IL-10 gene are reported to be linked with susceptibility to the development of schizophrenia. [23],[24],[25],[26] However, data is limited and inconsistent,therefore do not allow drawing unequivocal conclusions. Inthis study, we aimed to investigate the association between IL-10 gene polymorphismsin promoter region at -1082, -819, and -592 loci and susceptibility to schizophrenia in Saudi cohort.


  Materials and Methods Top


Subjects

The study population was composed of a total of 392 unrelated Saudi subjects including 181 schizophrenia patients recruited from the outpatient psychiatric clinic of Prince Sultan Military Medical City (PSMMC) Riyadh, Saudi Arabia and 211 age- and sex-matched healthy volunteers. The diagnosis of schizophrenia was based on the criteria mentioned in American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, DSM-IV-TR version. This criterion uses the self-reported experience of the patient and reported abnormalities in behavior and a comprehensive clinical assessment by a neuropsychiatrist. To ensure the diagnostic reliability, a systemic search into the case notes of the patients was made. Out of 200 initially selected schizophrenia patients,19 patients failedto meet explicit stated criteria, hence were excluded and only 181 patients were included in this study. Among the confirmed 181 cases of schizophrenia, there were 53 females and 128 males with mean age of 39 ± 12.5 years and mean disease duration of 9 ± 4.5 years. Age of onset of disease ranged from 19 to 64 years. The female to male ratio of schizophrenia patients in our study was 1:2.5. The control group consisted of 61 females and 150 males with mean age of 36 ± 10 years.

If diagnoses of schizophrenia was confirmed by above mentioned criteria, patients were further assessed for positive and negative symptoms using Positive or Negative Syndrome Scale (PANSS) involving further clinical interview, cognitive testing, motor assessment, and careful review of medical and historical records as described by Kay et al. [27] All the subjects in control group were screened using a questionnaire about the health status and excluded if they had any history of neurological, psychiatric, or medical disorders or had a past or present involvement in substance abuse. Control subjects less than 26-years-old and having first- or second-degree relatives with schizophrenia or any psychiatric disorder were excluded. A number of baseline parameters to rule out any psychotic illness were adopted as described by Johnstone et al. [28] This study was approved by the ethical committee of the hospital and informed consent was obtained from each subject.

Polymerase chain reaction (PCR) amplification

Genomic DNA was extracted from the blood of schizophrenia patients and controls using the QIAamp R DNA mini kit (Qiagen, USA). IL-10 gene was amplified using amplification refractory mutation systems (ARMS)-PCR methodology [29] to detect any polymorphism involved at various loci viz:-592,-819, and -1082.The sets of primers used to amplify various types of polymorphism were as reported earlier. [30]

PCR amplification was carried out in Ready-To-Go PCR Beads (Amersham Biosciences, USA). Reaction consisted of 10 temperature cycles of denaturation for 15 s at 94°C, annealing for 50 s at 65°C, and extension for 40 s at 72°C. Then 25 cycles of denaturation for 20 s at 94°C, annealing for 50 s at 59°C, and extension for 50s at 72°C. Final extension was performed at 72°C for 7 min. A positive control was included in the PCR assay by amplification of the human growth hormones (HGH) gene. Electrophoresis of the PCR product was performed in 1.5% agarose gel, stained with ethidium bromide, and photographed.

Statistical analysis

The differences in genotype and allele frequencies between patients and controls were analyzed with the Fisher's exact test. P ≤ 0.05 was considered significant. The strength of the association of disease with respect to a particular genotype/allele was expressed with the odds ratio interpreted as relative risk (RR). The strength of the association of disease with respect to a particular genotype/allele was expressed with odds ratio interpreted as RR following the method of Woolf as described by Schallreuter et al. [31] RR indicates how many times more frequent a disease is in the positive subjects compared with allele/genotype-negative subjects. It is calculated for a genotype/allele that is increased or decreased in psoriasis patients compared to the frequency in normal Saudi subjects. RR was calculated using the following formula:



Preventive fraction (PF) indicates the hypothetical protective effect of one allele/genotype for a disease. It is calculated for negative associations (RR < 1) using the following formula. [32] Values of <1.0 indicate the protective effect of an allele/genotype against the manifestation of disease.




  Results Top


The demographic features of the participants are summarized in [Table 1]. The results of SNP for IL-10 G (-1082) A, IL-10 C (-592) A, IL-10 C (-819) T, and corresponding genotypesusing ARMS-PCR method are summarized in [Table 2], [Table 3], [Table 4].
Table 1: Demographic features of patients/controls

Click here to view
Table 2: Genotype and allele frequencies of interleukin-10 (-1082G/A) variants in schizophrenia patients and
matched controls


Click here to view
Table 3: Genotype and allele frequencies of interleukin-10 (-819C/T) variants in schizophrenia patients and
matched controls


Click here to view
Table 4: Genotype and allele frequencies of interleukin-10 (-592C/A) variants in schizophrenia patients and
matched controls


Click here to view


The frequency of -1082GG genotype was found to be significantly lower (P = 0.027) in schizophrenia patients (2.21%) as compared to controls subjects (7.53%). On the contrary, the frequency of heterozygous genotype GA was significantly higher (P = 0.0002) in patients (91.71%) as compared to control subjects (75.27%), whereas frequency of homozygous AA genotype was lower in patients (6.08%) as compared with controls (12.20 %). These results indicate that genotype -1082GA is susceptible to schizophrenia (RR = 3.636, EF = 0.393) while genotypes GG and AA are resistant to schizophrenia (RR = 0.278, PF = 0.363 and RR = 0.311, PF = 0.362 respectively, [Table 2].

The frequency of -819 CC genotype was significantly higher (P = 0.05) in the schizophrenia patients (51.93%) compared to controls (41.71 %), while CT showed a reverse pattern with lower frequency (38.12 %) in schizophrenia patients as compared to 48.34% in controls (P = 0.05). The frequency of homozygous TT genotype was similar in both schizophrenia and control samples (9.95%). The CT genotype is more common among the healthy controls indicating that the 819 CT genotype may have a protective effect on the susceptibility to schizophrenia (RR = 0.66,PF = 0.17), whereas CC genotype appears to be susceptible to schizophrenia (RR = 1.51, EF = 0.17) [Table 3].

The frequency of -592 CC genotype was significantly higher in schizophrenia patients as compared to controls (51.93 vs 41.71%, P = 0.05), while CA genotype was found to be significantly lower (P = 0.05) in schizophrenia patients (38.12%) compared to control subjects (48.34%). The frequency of homozygous AA genotype was similarin both schizophrenia and control samples (9.95%). The higher frequency of CA genotype among the healthy controls indicated that the individuals with -592CA genotype are protected against schizophrenia (RR = 0.66, PF = 0.17), while CC genotype at position -592 of IL-10 are susceptible to schizophrenia (P
= 0.05, RR = 1.51, and EF = 0.17) [Table 4].

Upon stratification of subjects into gender and with positive or negative symptoms, no significant difference was found in distribution of alleles and genotypes of all the three polymorphisms either with sex of patients or schizophrenia with positive or negative symptoms [Table 5] and [Table 6].
Table 5: Comparison of frequencies of interleukin-10 (-1082G/A) variants with negative or positive symptoms in
schizophrenia patients and controls


Click here to view
Table 6: Comparison of frequencies of interleukin-10 (-1082G/A) variants in female and male schizophrenia patients

Click here to view



  Discussion Top


In the present study, intermediate IL-10 producer genotype -1082 G/A showed positive association with schizophrenia as 91.71% of the patients have this genotype as compared to 75.27% of control subjects, suggesting that individuals having 1082 G/A genotype are more prone to schizophrenia. Similarly, another study showed that intermediate IL-10 producer genotype -1082 GA is susceptible to schizophrenia in Taiwanese. [25] Almoguera et al., [33] reported a significant association of IL-10-1082A allele with Spanish schizophrenia females. Contrary to these, significantly increased frequency of G allele was reported in the schizophrenia group in Polish, [24] Chinese, [23],[34] and Italians. [35] By contrast, the association between the schizophrenia and the presence of-1082G has not been found in Korean and Turkish populations. [16],[36]

The frequency of IL-10-819CC was significantly higher, whereas the frequency of IL-10-819CT, was significantly lower in schizophrenia patients compared to healthy controls. The genotype -819 CC has been reported to be a high producer of IL10, whereas CT and TT as intermediate and low producer, respectively. [37] These findings further indicated that genotypes associated with intermediate-high production of IL-10 are more prevalent in schizophrenia patients. The genotypes of IL-10- (592), being in linkage disequilibrium with the genotypes of IL-10- (819) followed the pattern similar to those for frequencies of -819 in schizophrenia patients and healthy controls. The frequency of IL-10-592CC was also significantly higher in schizophrenia patients compared to healthy controls. However, contradictory reports are available from different ethnicities on the association between schizophrenia and IL-10-592C/A polymorphism. It has been reported as the statistically significant polymorphism in Chinese. [23] and Turkish patients with schizophrenia. [16] On the other hand,-592 C/A polymorphism had no association with both allele and genotype distributions in Italian. [35] and Korean schizophrenia patients. [36]

The genotypes of IL-10; -1082GA, -819CC, and -592CC (ACC haplotype); known to be associated with intermediate production of IL-10 are more prevalent in our schizophrenia patients indicating the possible association with susceptibility of schizophrenia which is supported by the finding that the schizophrenia patients show statistically significant increased expression of IL-10 as compared to controls. [7],[9],[13],[14],[15] Considering IL-10 gene promoter haplotypes, GCC in Italians. [35] and Chinese,(34) whereas GTA in Turkish. [16] and Chinese population, [23] both associated with high IL-10 production, have also been linked to schizophrenia. It seems that IL-10 might correlate to schizophrenia based on the hypotheses of Th2-like immunity shift of susceptible allele carrier.

There was no significant association of IL-10 polymorphisms with positive or negative symptoms of schizophrenia in our study. However, recently Sun et al, [38] reported that the interaction of the promoter of IL-10 rs1800872 and dopamine beta-hydroxylase (DBH) rs72393728 polymorphism is significantly associated with the PANSS general score, and suggested that the interaction of their variants may play a role in psychopathology of the general symptoms on PANSS in schizophrenic patients in a northern Chinese Han population.

Earlier published reports and present study indicate that IL-10 promoter polymorphisms may enhance the vulnerability of schizophrenia and many diseases, [26],[39],[40],[41],[42],[43],[44],[45],[46],[47],[48],[49] while may also exert a protective effect against others. [50],[51],[52],[53] It has been confirmed by the twin and family studies that ~75% of the variations in IL-10 production is genetically determined. [54] Furthermore, there are intrapopulation differences in the genetic control of IL-10 production by various alleles of the promoter region. Hence, the share of the promoter polymorphism may be different depending on the population. [36],[55]

The exact mechanism by which IL-10 affects the susceptibility/pathogenesis of schizophrenia is far from clear. It participates in the regulation of the immune response at several levels. [56] IL-10 regulates the inflammatory response, by inhibiting proinflammatory Th1 cytokines production, [57],[58] and it is constitutively expressed during fetal brain development in humans. [59] IL-10 cytokine downregulates the expression of major histocompatibility complex (MHC) class I and II molecules. [60],[61],[62],[63] It also has potent stimulatory effects on B lymphocytes, resulting in increased production of immunoglobulin and DNA replication. [60] Some immune-stimulating effects of IL-10 have been documented, where it induces activated B cells to secrete large amounts of IgG, IgA, and IgM and in combination with IL-4 results in the secretion of four immunoglobulin isotypes. Thus, increased levels of IL-10 may also play a role in the amplification of humoral responses in some diseases as suggested by Rousset et al. [60]

There is evidence of the role of IL-10 in the neurodevelopmental abnormalities found in schizophrenia. [64] It has been suggested that the genetically determined differences in IL-10 production could lead to behavioral abnormalities in the adulthood after prenatal immune challenge or innate immune imbalances. It has also been pointed out that not only an excess of proinflammatory cytokines, but also an imbalance between both classes of cytokines during development might alter normal brain functions in adult life. [64]

The immune system have been linked to schizophrenia, through candidate-gene, [24],[25],[35] pathway-based, [38] and genome-wide association. [65] approaches that have produced evidence of the immune system involvement in schizophrenia. The present study addresses the significant association of IL-10 promoter polymorphisms with Saudi schizophrenia patients as a case-control study.


  Conclusion Top


In conclusion, our results of IL-10 polymorphism in schizophrenia suggested that GA genotype at -1082 position together with CC genotypes at positions -592 and -819 of IL-10 genemight be susceptible to the development of schizophrenia. The genotypes 592 CA, 819 CT, 1082 GG, and 1082 AA of IL-10 gene, maybe protective against schizophrenia in Saudi test population. To our knowledge, this is the first study that examined IL-10 polymorphism in schizophrenia patients from Arabian ethnicity. However, further studies are warranted to investigate IL-10 polymorphisms in larger population samples as well as in schizophrenia affected families.


  Acknowledgment Top


The authors thank S. Sadaf Rizvi and Mohammad Al-Asmari for their help with laboratory work.

 
  References Top

1.
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005;2:e141.  Back to cited text no. 1
    
2.
McGrath J, Saha S, Chant D, Welham J. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76.  Back to cited text no. 2
    
3.
Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry 2010;22:417-28.  Back to cited text no. 3
    
4.
Paek MJ, Kang UG. How many genes are involved in schizophrenia? A simple simulation. Prog Neuropsychopharmacol Biol Psychiatry 2012;38:302-9.  Back to cited text no. 4
    
5.
Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD, et al. Convergent functional genomics of schizophrenia: From comprehensive understanding to genetic risk prediction. Mol Psychiatry 2012;17:887-905.  Back to cited text no. 5
    
6.
Plata-Salamán C, Turrin N. Cytokine action in the brain. Mol Psychiatr 1999;4:302.  Back to cited text no. 6
    
7.
Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: Differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 2011;33:268-74.  Back to cited text no. 7
    
8.
Singh B, Bera NK, Nayak CR, Chaudhuri TK. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009;47:1-5.  Back to cited text no. 8
    
9.
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biol Psychiatry 2011;70: 663-71.  Back to cited text no. 9
    
10.
Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry 2008;63:801-8.  Back to cited text no. 10
    
11.
Schwarz MJ, Muller N, Riedel M, Ackenheil M. The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001;56:483-6.  Back to cited text no. 11
    
12.
Freudenreich O, Brockman MA, Henderson DC, Evins AE, Fan X, Walsh JP, et al. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res 2010;176:99-102.  Back to cited text no. 12
    
13.
Maes M, Bocchio Chiavetto L, Bignotti S, Battisa TG, Pioli R, Boin F, et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 2000;10:119-24.  Back to cited text no. 13
    
14.
Cazzulo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M. Cytokines production in chronic schizophrenia patients with or without paranoid behavior. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:947-57.  Back to cited text no. 14
    
15.
Kamiñska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slemp H, Kandefer-Szerszeñ M. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 2001;49:439-45.  Back to cited text no. 15
    
16.
Ozbey U, Tug E, Namli M. Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. World J Biol Psychiatry 2009;10:461-8.  Back to cited text no. 16
    
17.
Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis 2008;12:713-26.  Back to cited text no. 17
    
18.
D'Alfonso S, Rampi M, Rolando V, Giordano M, Momigliano-Richiardi P. New polymorphisms in the IL-10 promoter region. Genes Immun 2000;1:231-3.  Back to cited text no. 18
    
19.
Mormann M, Rieth H, Hua TD, Assohou C, Roupelieva M, Hu SL, et al. Mosaics of gene variations in the interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used. Genes Immun 2004;5:246-55.  Back to cited text no. 19
    
20.
Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998;95: 9465-70.  Back to cited text no. 20
    
21.
Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: Differential effects on production and allele frequencies. Genes Immun 2000;1:185-90.  Back to cited text no. 21
    
22.
Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.  Back to cited text no. 22
    
23.
Yu L, Yang MS, Zhao J. Shi YY, Zhao XZ, Yang JD, et al. An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population. Schizophr Res 2004;71:179-83.  Back to cited text no. 23
    
24.
Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A, et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia - A case control study. J Mol Neurosci 2010;42:112-9.  Back to cited text no. 24
    
25.
Lung FW, Yang MC, Shu BC. The interleukin 10 promoter haplotype ACA and the long-form variant of the DRD4 uVNTR polymorphism are associated with vulnerability to schizophrenia. Psychiatry Res 2011;188:294-6.  Back to cited text no. 25
    
26.
Gao L, Li Z, Chang S, Wang J. Association of interleukin-10 polymorphisms with schizophrenia: A meta-analysis. PLoS One 2014;9:e90407.  Back to cited text no. 26
    
27.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.  Back to cited text no. 27
    
28.
Johnstone EC, Ebmeier KP, Miller P, Owens DG, Lawrie SM. Predicting schizophrenia: Findings from the Edinburgh high-risk study. Br J Psychiatry 2005;186:18-25.  Back to cited text no. 28
    
29.
Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β and TGF-β1 gene polymorphisms. Transpl Immunol 1999;7:127-8.  Back to cited text no. 29
    
30.
Abanmi A, Al Harthi F, Al Baqami R, Al Assaf S, Zouman A, Arfin M, et al. Association of HLA loci alleles and antigens in Saudi patients with vitiligo. Arch Dermatol Res 2006;298: 347-52.  Back to cited text no. 30
    
31.
Schallreuter KU, Levenig C, Kuhnl P, Loliger C, Hohl-Tehari M, Berger J. Histocompatability antigens in vitiligo: Hamburg study on 102 patients from Northern Germany. Dermatology 1993;187:186-92.  Back to cited text no. 31
    
32.
Savejgaard A, Platz P, Ryder LP. HLA and disease 1982 - A survey. Immunol Rev 1983;70:193-218.  Back to cited text no. 32
    
33.
Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Lopez-Rodriguez R, Fernandez-Navarro P, et al; Spanish Consortium of Pharmacogenetics Research in Schizophrenia. ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: A case control study. BMC Med Genet 2011;12:81.  Back to cited text no. 33
    
34.
He G, Zhang J, Li XW, Chen WY, Pan YX, Yang FP, et al. Interleukin-10-1082 promoter polymorphism is associated with schizophrenia in a Han Chinese sib-pair study. Neurosci Lett 2006;394:1-4.  Back to cited text no. 34
    
35.
Bocchio Chiavetto L, Boin F, Zanardini R, Popoli M, Michelato A, Bignotti S, et al. Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol Psychiatry 2002;51:480-4.  Back to cited text no. 35
    
36.
Jun TY, Lee KU, Pae CU, Chae JH, Bahk WM, Kim KS, et al. Polymorphisms of interleukin-4 promoter and receptor gene for schizophrenia in the Korean population. Psychiatry Clin Neurosci 2003;53:283-8.  Back to cited text no. 36
    
37.
Addas-Carvalho M, Salles TS, Saad ST. The association of cytokine gene polymorphism with febrile non-hemolytic transfusion reaction in multitransfused patients. Transfus Med 2006;19:184-91.  Back to cited text no. 37
    
38.
Sun J, Jia P, Fanous AH, van den Oord E, Chen X, Riley BP, et al. Schizophrenia gene networks and pathways and their applications for novel candidate gene selection. PLoS One 2010;5:e11351.  Back to cited text no. 38
    
39.
Inoue N, Watanabe M, Wada M, Morita M, Hidaka Y, Iwatani Y. IL-10-592A/C polymorphism is associated with severity of Hashimoto's disease. Cytokine 2013;64:370-4.  Back to cited text no. 39
    
40.
Qin SY, Jiang HX, Lu DH, Zhou Y. Association of interleukin-10 polymorphisms with risk of irritable bowel syndrome: A meta-analysis. World J Gastroenterol 2013;19:9472-80.  Back to cited text no. 40
    
41.
Peng H, Wang W, Zhou M, Li R, Pan HF, Ye DQ. Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus. Clin Rheumatol 2013;32:1255-66.  Back to cited text no. 41
    
42.
Kutluturk F, Yarman S, Sarvan FO, Kekik C. Association of cytokine gene polymorphisms (IL6, IL10, TNF-α, TGF-β and IFN-ã) and Graves' disease in Turkish population. Endocr Metab Immune Disord Drug Targets 2013;13:163-7.  Back to cited text no. 42
    
43.
Liu P, Song J, Su H, Li L, Lu N, Yang R, et al. IL-10 gene polymorphisms and susceptibility to systemic lupus erythematosus: A meta-analysis. PLoS One 2013;8:e69547.  Back to cited text no. 43
    
44.
Davis LA, Whitfield E, Cannon GW, Wolff RK, Johnson DS, Reimold AM, et al. Association of rheumatoid arthritis susceptibility gene with lipid profiles in patients with rheumatoid arthritis. Rheumatology (Oxford) 2014;53:1014-21.  Back to cited text no. 44
    
45.
Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, Chou MC, et al. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 2005;50:291-7.  Back to cited text no. 45
    
46.
Monneret G, Finck ME, Venet F, Debard AL, Bohe J, Bienvenu J, et al. The anti-inflammatory response dominates after septic shock: Association of low moncyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 2004;95: 193-8.  Back to cited text no. 46
    
47.
Fernandez L, Martinez A, Mendoza JL, Urcelay E, Fernandez-Arquero M, Garcia-Paredes J, et al. Interleukin-10 polymorphisms in Spanish patients with IBD. Inflamm Bowel Dis 2005;11:739-43.  Back to cited text no. 47
    
48.
Gong MN, Thompson BT, Williams PL, Zhou W, Wang MZ, Pothier L, et al. Interleukin-10 polymorphism in position-1082 and acute respiratory distress syndrome. Eur Respir J 2006;27:674-81.  Back to cited text no. 48
    
49.
Munshi A, Rajeshwar K, Kaul S, Al-Hazzani A, Alshatwi AA, Sai Babu M, et al. Interleukin-10-1082 promoter polymorphism and ischemic stroke risk in a South Indian population. Cytokine 2010;52:221-4.  Back to cited text no. 49
    
50.
Lio D, Candore G, Crivello A, Scola L, Colonna-Romano G, Cavallone L, et al. Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: Genetic background of male centenarians is protective against coronary heart disease. J Med Genet 2004;41:790-4.  Back to cited text no. 50
    
51.
Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Koppel H, et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res 2005;90:113-5.  Back to cited text no. 51
    
52.
Shin HD, Park BL, Kim YH, Cheong HS, Lee IH, Park SK. Common interleukin 10 polymorphism associated with decreased risk of tuberculosis. Exp Mol Med 2005;37: 128-32.  Back to cited text no. 52
    
53.
Malhotra D, Darvishi K, Sood S, Sharma S, Grover C, Relhan V, et al. IL-10 promoter single nucleotide polymorphisms are significantly associated with resistance to leprosy. Hum Genet 2005;118:295-300.  Back to cited text no. 53
    
54.
Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-3.  Back to cited text no. 54
    
55.
Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon- therapy. J Med Virol 2001;65:510-6  Back to cited text no. 55
    
56.
Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993;11: 165-90.  Back to cited text no. 56
    
57.
Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146:3444-51.  Back to cited text no. 57
    
58.
Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-22.  Back to cited text no. 58
    
59.
Mousa A, Seiger A, Kjaeldgaard A, Bakhiet M. Human first trimester forebrain cells express genes for inflammatory and anti-inflammatory cytokines. Cytokine 1999;11:55-60.  Back to cited text no. 59
    
60.
Rousset F, Garcia E, Defrance T, Vezzio N, Peronne C, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-3.  Back to cited text no. 60
    
61.
Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997;71:630-7.  Back to cited text no. 61
    
62.
de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down regulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-24.  Back to cited text no. 62
    
63.
Tsuruma T, Yagihashi A, Torigoe T, Sato N, Kijuchi K, Watanabe N, et al. Interleukin-10 reduces natural killer sensitivity and down regulates MHC class I expression on H-ras-Transformed cells. Cell Immunol 1998;184:121-8.  Back to cited text no. 63
    
64.
Meyer U, Murray PJ, Urwyler A, Yee BK, Schedlowski M, Feldon J. Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol Psychiatry 2008;13:208-21.  Back to cited text no. 64
    
65.
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al; Genetic Risk and Outcome in Psychosis (GROUP). Common variants conferring risk of schizophrenia. Nature 2009;460:744-7.  Back to cited text no. 65
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]


This article has been cited by
1 C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review
Guillaume Fond,Christophe Lançon,Pascal Auquier,Laurent Boyer
Frontiers in Psychiatry. 2018; 9
[Pubmed] | [DOI]
2 Family-based association study of interleukin 10 (IL10) and interleukin 10 receptor alpha (IL10RA) functional polymorphisms in schizophrenia in Polish population
Pawel Kapelski,Maria Skibinska,Malgorzata Maciukiewicz,Joanna Pawlak,Dorota Zaremba,Joanna Twarowska-Hauser
Journal of Neuroimmunology. 2016; 297: 92
[Pubmed] | [DOI]
3 Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study
Bram. P. Prins,Ali Abbasi,Anson Wong,Ahmad Vaez,Ilja Nolte,Nora Franceschini,Philip E. Stuart,Javier Guterriez Achury,Vanisha Mistry,Jonathan P. Bradfield,Ana M. Valdes,Jose Bras,Aleksey Shatunov,Chen Lu,Buhm Han,Soumya Raychaudhuri,Steve Bevan,Maureen D. Mayes,Lam C. Tsoi,Evangelos Evangelou,Rajan P. Nair,Struan F. A. Grant,Constantin Polychronakos,Timothy R. D. Radstake,David A. van Heel,Melanie L. Dunstan,Nicholas W. Wood,Ammar Al-Chalabi,Abbas Dehghan,Hakon Hakonarson,Hugh S. Markus,James T. Elder,Jo Knight,Dan E. Arking,Timothy D. Spector,Bobby P. C. Koeleman,Cornelia M. van Duijn,Javier Martin,Andrew P. Morris,Rinse K. Weersma,Cisca Wijmenga,Patricia B. Munroe,John R. B. Perry,Jennie G. Pouget,Yalda Jamshidi,Harold Snieder,Behrooz Z. Alizadeh,Phillipa J. Hay
PLOS Medicine. 2016; 13(6): e1001976
[Pubmed] | [DOI]
4 Association study of functional polymorphisms in interleukins and interleukin receptors genes: IL1A, IL1B, IL1RN, IL6, IL6R, IL10, IL10RA and TGFB1 in schizophrenia in Polish population
Pawel Kapelski,Maria Skibinska,Malgorzata Maciukiewicz,Monika Wilkosc,Dorota Frydecka,Agata Groszewska,Beata Narozna,Monika Dmitrzak-Weglarz,Piotr Czerski,Joanna Pawlak,Aleksandra Rajewska-Rager,Anna Leszczynska-Rodziewicz,Agnieszka Slopien,Dorota Zaremba,Joanna Twarowska-Hauser
Schizophrenia Research. 2015; 169(1-3): 1
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Materials and Me...
Results
Discussion
Conclusion
Acknowledgment
References
Article Tables

 Article Access Statistics
    Viewed1652    
    Printed50    
    Emailed0    
    PDF Downloaded296    
    Comments [Add]    
    Cited by others 4    

Recommend this journal